Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience

por Angelo, Maria-Genalin, Zima, Julia, Tavares Da Silva, Fernanda, Baril, Laurence, Arellano, Felix
Publicado 2014

Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme

por Angelo, Maria-Genalin, David, Marie-Pierre, Zima, Julia, Baril, Laurence, Dubin, Gary, Arellano, Felix, Struyf, Frank
Publicado 2014

Investigating Reports of Complex Regional Pain Syndrome: An Analysis of HPV-16/18-Adjuvanted Vaccine Post-Licensure Data

por Huygen, Frank, Verschueren, Kristin, McCabe, Candida, Stegmann, Jens-Ulrich, Zima, Julia, Mahaux, Olivia, Van Holle, Lionel, Angelo, Maria-Genalin
Publicado 2015

Risk of new onset autoimmune disease in 9- to 25-year-old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom

por Willame, Corinne, Rosillon, Dominique, Zima, Julia, Angelo, Maria-Genalin, Stuurman, Anke L., Vroling, Hilde, Boggon, Rachael, Bunge, Eveline M., Pladevall-Vila, Manel, Baril, Laurence
Publicado 2016

Safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in adolescents aged 12–15 years: Interim analysis of a large community-randomized controlled trial

por Lehtinen, Matti, Eriksson, Tiina, Apter, Dan, Hokkanen, Mari, Natunen, Kari, Paavonen, Jorma, Pukkala, Eero, Angelo, Maria-Genalin, Zima, Julia, David, Marie-Pierre, Datta, Sanjoy, Bi, Dan, Struyf, Frank, Dubin, Gary
Publicado 2016